New York, Feb 22, 2026, 13:46 EST — The market is closed.
- UnitedHealth shares finished Friday about flat, then slipped slightly after the bell.
- Monday’s session opens with Medicare Advantage payment policy taking center stage for investors.
- This week’s federal comment deadline looms, with the final rate decision not due until April.
UnitedHealth Group Incorporated shares finished Friday at $290.00, barely nudging higher by 7 cents, or 0.02%. After hours, the stock eased back to $289.19, down 0.28%. In the regular session, trading ranged from $285.55 to $290.80 on roughly 6.9 million shares.
UnitedHealth shares ended flat, a key detail since the stock often serves as a proxy for policy risk tied to U.S. managed care. As the weekend pauses U.S. market action, investors are watching for fresh policy cues ahead of Monday morning.
The Centers for Medicare & Medicaid Services is accepting feedback on its 2027 Medicare Advantage and Part D proposals until 11:59 p.m. ET on Feb. 25, with the final Rate Announcement expected by April 6. The agency estimates the plan would bump average Medicare Advantage payments by just 0.09% in 2027. It also flagged changes to risk adjustment, tightening rules on which diagnosis data get factored into payment levels. CMS Administrator Dr. Mehmet Oz said the package is about “making sure Medicare Advantage works better for the people it serves.” Centers for Medicare & Medicaid Services
UnitedHealth held up better than most managed-care rivals Friday. Cigna slipped 2.0%, Elevance lost 1.5%, CVS shed 0.8%, and Humana was off 0.4%, while UnitedHealth managed to tick higher.
Elsewhere, the market pushed upward. U.S. stocks closed out Friday with gains after the Supreme Court struck down President Donald Trump’s global tariffs—a move traders took as curbing the reach of the latest trade disruption. The S&P 500 finished up 0.69%, the Nasdaq advanced 0.90%, while the Dow climbed 0.47%.
UnitedHealth shareholders often find the policy schedule matters more than daily price moves. Medicare Advantage, which offers a private-sector substitute for standard Medicare, gets its reimbursement framework set by rulemakers—those decisions flow right into how insurers set prices, structure benefits, and protect their margins.
Last month, UnitedHealth drew notice after projecting an unusual drop in revenue and highlighting ongoing government reimbursement pressure. The company is targeting more than $439 billion in revenue for 2026, with adjusted earnings per share north of $17.75. It also sees the medical care ratio for that year coming in around 88.8%—that’s the cut of premiums spent on care. James Harlow of Novare Capital Management, commenting on the Medicare proposal at the time, said it “starts to bring in worries about 2027 earnings growth.” CEO Stephen Hemsley, for his part, assured investors: “Momentum inside this organization is palpable.” Reuters
The downside scenario isn’t hard to map out. Should the Medicare Advantage rate update end up near the proposal, and if stricter risk-adjustment rules start slicing payments linked to diagnosis coding, insurers might pivot to sharper benefit cuts, shrink networks, or even pull out of some markets. Any gains from repricing risk getting overshadowed if medical utilization runs high.
With no investor events on the calendar at its investor relations site, UnitedHealth traders are left watching policy news and broader sector moves for cues in the short term.
First up, the CMS comment window closes Feb. 25, with the final rate decision expected by April 6 at the latest. That leaves Monday as a battleground for positioning—managed-care names could see action as defensives, or get treated as policy plays depending on sentiment.
